CARELINK™ SYSTEM Therapy Management Software

CareLink™ system software is a diabetes therapy management software for healthcare professionals. This software helps healthcare professionals to better manage patients on diabetes therapy by transforming data from insulin pumps, continuous glucose monitors and blood glucose meters into trends, patterns and insights about their patients’ glycemic control. The CareLink™ system provides easier access to vital insights. 

REQUEST MORE INFORMATION

Overview

Clearer Insights. Easier Access.

CareLink™ software transforms raw data into personalized insights that can improve diabetes management by helping you make confident decisions about your patients' therapy.

Access CareLink™ software via any browser or device — your patients' data is at your fingertips wherever and whenever you need it.

COMPREHENSIVE INSIGHTS FOR WELL-INFORMED DECISIONS

 

 

CareLink™ reports help you visualize your patient’s diabetes information with charts and statistics. CareLink™ software reports intelligently analyze all the data to highlight observations and patterns, helping you make recommendations you are confident about. That’s why 87% of clinical diabetes educators choose CareLink™ software as their preferred diabetes software.1

With CareLink™ software you can:

  • Display all of your patient’s meter, continuous glucose monitoring (CGM), and insulin pump data in one place with CareLink™ software reports.
  • Link to patient’s CareLink™ Personal software to automatically get the most updated information.
  • Use new reports to compare glycemic control between two time periods and visualize long-term glycemic control, glycemic variability, and time in target range.

NEW REPORTS HELP OPTIMIZE MINIMED™ 670G SYSTEM USAGE

ASSESSMENT AND PROGRESS REPORT

  • Unique opportunity to compare glycemic control between two time periods, so you can evaluate any progress or improvement
  • Use list of Auto Mode exits to counsel patients on behaviors to spend more time in Auto Mode

Weekly Review Report

  • Daily details to review insulin delivery with active insulin shading, glucose response, and algorithm control
  • Auto Mode Exit Reasons allow you to focus less on the problem and more on the solution

Meal Bolus Wizard Report

  • Shows effect of boluses that the patient has taken for their meals and overnight
  • Discuss carbohydrate counting, insulin carb ratio, and other settings to make sure meals are being handled appropriately
The MiniMed 670G, Guardian Sensor 3, and glucose meter.

HELP PATIENTS SEE THE WHOLE PICTURE

Male physician and male patient discuss therapy options in a clinical setting.

CareLink™ Personal software is a free web-based program that collects information directly from patients’ diabetes management systems and syncs with your CareLink™ software. Using CareLink™ Personal software helps keep patients informed and improves their engagement with therapy.

Benefits of CareLink™ Personal software:

  • Gives doctors and patients the same reports
  • Collaborative approach shifts focus to the patient’s goals
  • Information that leads to a deeper understanding
  • Discover patterns and trends

Visit medtronicdiabetes.com/carelink-info for more resources to share with your patients.

SIGN IN TO CARELINK

Access your patient data through the CareLink™ system.

LOG IN NOW

USER GUIDES AND MANUALS

Browse our library to find reference materials for your Medtronic Diabetes products.

VISIT LIBRARY
1

dQ&A Diabetes Educator Perspectives Survey, Q3 2015. 428 total respondents.

Important Safety Information: MiniMed™ 670G System
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.

WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.

© 2020 Medtronic MiniMed, Inc. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic™. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.

Ascensia Diabetes Care Logo

Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.